{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:43:55Z","timestamp":1759797835535,"version":"build-2065373602"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["20\/10544-1","20\/10664-7"],"award-info":[{"award-number":["20\/10544-1","20\/10664-7"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03530-y","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T12:51:26Z","timestamp":1759755086000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Alpha 5 integrin as a prognostic biomarker for survival in carcinomas: a systematic review"],"prefix":"10.1007","volume":"16","author":[{"given":"Natalie Ap.","family":"Rodrigues Fernandes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milena Moraes","family":"de Carvalho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e9lio Fernando Ferreira","family":"Soares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wafa","family":"Wahbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuula","family":"Salo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Al-Samadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Rossa Junior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"issue":"3","key":"3530_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"3530_CR2","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423\u201337.","journal-title":"Nat Med"},{"issue":"9","key":"3530_CR3","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41568-018-0038-z","volume":"18","author":"H Hamidi","year":"2018","unstructured":"Hamidi H, Ivaska J. Every step of the way: integrins in cancer progression and metastasis. Nat Rev Cancer. 2018;18(9):533\u201348.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"3530_CR4","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/gb-2007-8-5-215","volume":"8","author":"Y Takada","year":"2007","unstructured":"Takada Y, Ye X, Simon S. The integrins. Genome Biol. 2007;8(5):215.","journal-title":"Genome Biol"},{"key":"3530_CR5","doi-asserted-by":"publisher","first-page":"13329","DOI":"10.2147\/OTT.S273803","volume":"13","author":"J Hou","year":"2020","unstructured":"Hou J, et al. The roles of integrin \u03b15\u03b21 in human cancer. Onco Targets Ther. 2020;13:13329\u201344.","journal-title":"Onco Targets Ther"},{"issue":"2","key":"3530_CR6","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1096\/fj.03-0568fje","volume":"18","author":"KK Tomczak","year":"2004","unstructured":"Tomczak KK, et al. Expression profiling and identification of novel genes involved in myogenic differentiation. Faseb J. 2004;18(2):403\u20135.","journal-title":"Faseb J"},{"issue":"3","key":"3530_CR7","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/cdd.2012.138","volume":"20","author":"DA Brafman","year":"2013","unstructured":"Brafman DA, et al. Regulation of endodermal differentiation of human embryonic stem cells through integrin-ECM interactions. Cell Death Differ. 2013;20(3):369\u201381.","journal-title":"Cell Death Differ"},{"issue":"3","key":"3530_CR8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.cmet.2005.08.006","volume":"2","author":"J Liu","year":"2005","unstructured":"Liu J, et al. Changes in integrin expression during adipocyte differentiation. Cell Metab. 2005;2(3):165\u201377.","journal-title":"Cell Metab"},{"issue":"7","key":"3530_CR9","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/nrm3599","volume":"14","author":"D Bouvard","year":"2013","unstructured":"Bouvard D, et al. Integrin inactivators: balancing cellular functions in vitro and in vivo. Nat Rev Mol Cell Biol. 2013;14(7):430\u201342.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"3530_CR10","doi-asserted-by":"publisher","first-page":"5120","DOI":"10.1038\/s41467-020-18794-x","volume":"11","author":"J Winkler","year":"2020","unstructured":"Winkler J, et al. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat Commun. 2020;11(1):5120.","journal-title":"Nat Commun"},{"key":"3530_CR11","doi-asserted-by":"crossref","unstructured":"Lu L, et al. Targeting integrin \u03b15 in fibroblasts potentiates colorectal cancer response to PD-L1 blockade by affecting extracellular-matrix deposition. J Immunother Cancer. 2023;11(12).","DOI":"10.1136\/jitc-2023-007447"},{"issue":"4","key":"3530_CR12","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0002-9440(10)65005-5","volume":"156","author":"S Kim","year":"2000","unstructured":"Kim S, et al. Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am J Pathol. 2000;156(4):1345\u201362.","journal-title":"Am J Pathol"},{"issue":"2","key":"3530_CR13","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s00280-018-3622-8","volume":"82","author":"CD Weekes","year":"2018","unstructured":"Weekes CD, et al. Phase I study of the anti-\u03b15\u03b21 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018;82(2):339\u201351.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"3530_CR14","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ygyno.2010.12.362","volume":"121","author":"KM Bell-McGuinn","year":"2011","unstructured":"Bell-McGuinn KM, et al. A phase II, single-arm study of the anti-\u03b15\u03b21 integrin antibody Volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol. 2011;121(2):273\u20139.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"3530_CR15","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s00280-014-2576-8","volume":"74","author":"J Mateo","year":"2014","unstructured":"Mateo J, et al. A first-in-human study of the anti-\u03b15\u03b21 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014;74(5):1039\u201346.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"3530_CR16","first-page":"273","volume":"5","author":"V Ramakrishnan","year":"2006","unstructured":"Ramakrishnan V, et al. Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol. 2006;5(4):273\u201386.","journal-title":"J Exp Ther Oncol"},{"issue":"7544","key":"3530_CR17","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nature14323","volume":"519","author":"P Vitorino","year":"2015","unstructured":"Vitorino P, et al. MAP4K4 regulates integrin-FERM binding to control endothelial cell motility. Nature. 2015;519(7544):425\u201330.","journal-title":"Nature"},{"issue":"13","key":"3530_CR18","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1038\/onc.2010.532","volume":"30","author":"AK Mitra","year":"2011","unstructured":"Mitra AK, et al. Ligand-independent activation of c-Met by fibronectin and \u03b1(5)\u03b2(1)-integrin regulates ovarian cancer invasion and metastasis. Oncogene. 2011;30(13):1566\u201376.","journal-title":"Oncogene"},{"issue":"4","key":"3530_CR19","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.3892\/or.2016.4985","volume":"36","author":"C Gong","year":"2016","unstructured":"Gong C, et al. miR-17 inhibits ovarian cancer cell peritoneal metastasis by targeting ITGA5 and ITGB1. Oncol Rep. 2016;36(4):2177\u201383.","journal-title":"Oncol Rep"},{"issue":"5","key":"3530_CR20","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1002\/jcb.22626","volume":"110","author":"Z Fang","year":"2010","unstructured":"Fang Z, et al. Functional Elucidation and methylation-mediated downregulation of ITGA5 gene in breast cancer cell line MDA-MB-468. J Cell Biochem. 2010;110(5):1130\u201341.","journal-title":"J Cell Biochem"},{"issue":"2","key":"3530_CR21","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.bbrc.2014.03.002","volume":"446","author":"D Liu","year":"2014","unstructured":"Liu D, et al. Sine oculis homeobox homolog 1 promotes \u03b15\u03b21-mediated invasive migration and metastasis of cervical cancer cells. Biochem Biophys Res Commun. 2014;446(2):549\u201354.","journal-title":"Biochem Biophys Res Commun"},{"key":"3530_CR22","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"issue":"1","key":"3530_CR23","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, et al. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210.","journal-title":"Syst Rev"},{"issue":"10","key":"3530_CR24","first-page":"2127","volume":"18","author":"Z Munn","year":"2020","unstructured":"Munn Z, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth. 2020;18(10):2127\u201333.","journal-title":"JBI Evid Synth"},{"issue":"7","key":"3530_CR25","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/0008-5472.CAN-07-5167","volume":"68","author":"K Sawada","year":"2008","unstructured":"Sawada K, et al. Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res. 2008;68(7):2329\u201339.","journal-title":"Cancer Res"},{"issue":"2","key":"3530_CR26","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s13402-019-00486-4","volume":"43","author":"X Li","year":"2020","unstructured":"Li X, et al. The Exosomal integrin \u03b15\u03b21\/AEP complex derived from epithelial ovarian cancer cells promotes peritoneal metastasis through regulating mesothelial cell proliferation and migration. Cell Oncol (Dordr). 2020;43(2):263\u201377.","journal-title":"Cell Oncol (Dordr)"},{"issue":"5","key":"3530_CR27","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1007\/s00404-021-06281-7","volume":"305","author":"S Krajnak","year":"2022","unstructured":"Krajnak S, et al. Role of integrins in the metastatic spread of high-grade serous ovarian cancer. Arch Gynecol Obstet. 2022;305(5):1291\u20138.","journal-title":"Arch Gynecol Obstet"},{"issue":"3","key":"3530_CR28","doi-asserted-by":"publisher","first-page":"839","DOI":"10.31557\/APJCP.2022.23.3.839","volume":"23","author":"TE Helal","year":"2022","unstructured":"Helal TE, et al. Epithelial-Mesenchymal transition markers in hcvassociated hepatocellular carcinoma: A multivariate follow up study. Asian Pac J Cancer Prev. 2022;23(3):839\u201349.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"10","key":"3530_CR29","doi-asserted-by":"publisher","first-page":"11983","DOI":"10.1002\/cam4.5873","volume":"12","author":"X Xu","year":"2023","unstructured":"Xu X, et al. ITGA5 promotes tumor angiogenesis in cervical cancer. Cancer Med. 2023;12(10):11983\u201399.","journal-title":"Cancer Med"},{"issue":"2","key":"3530_CR30","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1464-410X.2010.09534.x","volume":"107","author":"HM Behnsawy","year":"2011","unstructured":"Behnsawy HM, et al. Expression of integrin proteins in non-muscle-invasive bladder cancer: significance of intravesical recurrence after transurethral resection. BJU Int. 2011;107(2):240\u20136.","journal-title":"BJU Int"},{"issue":"12","key":"3530_CR31","doi-asserted-by":"publisher","first-page":"15588","DOI":"10.3390\/ijms131215588","volume":"13","author":"Z Hu","year":"2012","unstructured":"Hu Z, et al. Elevated levels of Lewis y and integrin \u03b15\u03b21 correlate with chemotherapeutic drug resistance in epithelial ovarian carcinoma. Int J Mol Sci. 2012;13(12):15588\u2013600.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"3530_CR32","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1016\/j.ajpath.2013.01.039","volume":"182","author":"C Ohyagi-Hara","year":"2013","unstructured":"Ohyagi-Hara C, et al. miR-92a inhibits peritoneal dissemination of ovarian cancer cells by inhibiting integrin \u03b15 expression. Am J Pathol. 2013;182(5):1876\u201389.","journal-title":"Am J Pathol"},{"issue":"2","key":"3530_CR33","first-page":"830","volume":"5","author":"LC Zhu","year":"2015","unstructured":"Zhu LC, et al. Membranous expressions of Lewis y and CAM-DR-related markers are independent factors of chemotherapy resistance and poor prognosis in epithelial ovarian cancer. Am J Cancer Res. 2015;5(2):830\u201343.","journal-title":"Am J Cancer Res"},{"key":"3530_CR34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.humpath.2015.09.029","volume":"48","author":"JJ Xie","year":"2016","unstructured":"Xie JJ, et al. Integrin \u03b15 promotes tumor progression and is an independent unfavorable prognostic factor in esophageal squamous cell carcinoma. Hum Pathol. 2016;48:69\u201375.","journal-title":"Hum Pathol"},{"key":"3530_CR35","doi-asserted-by":"publisher","first-page":"9609","DOI":"10.2147\/CMAR.S223201","volume":"11","author":"Y Deng","year":"2019","unstructured":"Deng Y, Wan Q, Yan W. Integrin \u03b15\/ITGA5 promotes the proliferation, migration, invasion and progression of oral squamous carcinoma by Epithelial-Mesenchymal transition. Cancer Manag Res. 2019;11:9609\u201320.","journal-title":"Cancer Manag Res"},{"issue":"9","key":"3530_CR36","doi-asserted-by":"publisher","first-page":"eaax2770","DOI":"10.1126\/sciadv.aax2770","volume":"5","author":"PR Kuninty","year":"2019","unstructured":"Kuninty PR, et al. ITGA5 Inhibition in pancreatic stellate cells attenuates desmoplasia and potentiates efficacy of chemotherapy in pancreatic cancer. Sci Adv. 2019;5(9):eaax2770.","journal-title":"Sci Adv"},{"issue":"12","key":"3530_CR37","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1002\/1878-0261.12583","volume":"13","author":"L Lu","year":"2019","unstructured":"Lu L, et al. Integrin \u03b15 subunit is required for the tumor supportive role of fibroblasts in colorectal adenocarcinoma and serves as a potential stroma prognostic marker. Mol Oncol. 2019;13(12):2697\u2013714.","journal-title":"Mol Oncol"},{"issue":"10","key":"3530_CR38","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/nrm1490","volume":"5","author":"W Guo","year":"2004","unstructured":"Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol. 2004;5(10):816\u201326.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"3530_CR39","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1159\/000362978","volume":"34","author":"BL Br\u00fccher","year":"2014","unstructured":"Br\u00fccher BL, Jamall IS. Cell-cell communication in the tumor microenvironment, carcinogenesis, and anticancer treatment. Cell Physiol Biochem. 2014;34(2):213\u201343.","journal-title":"Cell Physiol Biochem"},{"issue":"1","key":"3530_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2006.03.031","volume":"247","author":"MZ Gilcrease","year":"2007","unstructured":"Gilcrease MZ. Integrin signaling in epithelial cells. Cancer Lett. 2007;247(1):1\u201325.","journal-title":"Cancer Lett"},{"issue":"1","key":"3530_CR41","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc2748","volume":"10","author":"JS Desgrosellier","year":"2010","unstructured":"Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10(1):9\u201322.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"3530_CR42","first-page":"200","volume":"26","author":"R Wang","year":"2023","unstructured":"Wang R, Gao Y, Zhang H. ACTN1 interacts with ITGA5 to promote cell proliferation, invasion and epithelial-mesenchymal transformation in head and neck squamous cell carcinoma. Iran J Basic Med Sci. 2023;26(2):200\u20137.","journal-title":"Iran J Basic Med Sci"},{"issue":"1","key":"3530_CR43","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12943-023-01744-8","volume":"22","author":"Z Yuan","year":"2023","unstructured":"Yuan Z, et al. Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments. Mol Cancer. 2023;22(1):48.","journal-title":"Mol Cancer"},{"issue":"19\u201320","key":"3530_CR44","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1101\/gad.314617.118","volume":"32","author":"H Gonzalez","year":"2018","unstructured":"Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018;32(19\u201320):1267\u201384.","journal-title":"Genes Dev"},{"issue":"5","key":"3530_CR45","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nrc1877","volume":"6","author":"R Kalluri","year":"2006","unstructured":"Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6(5):392\u2013401.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"3530_CR46","doi-asserted-by":"publisher","first-page":"112765","DOI":"10.1016\/j.yexcr.2021.112765","volume":"406","author":"U Ngaokrajang","year":"2021","unstructured":"Ngaokrajang U, et al. Integrin \u03b15 mediates intrinsic cisplatin resistance in three-dimensional nasopharyngeal carcinoma spheroids via the Inhibition of phosphorylated ERK \/caspase-3 induced apoptosis. Exp Cell Res. 2021;406(2):112765.","journal-title":"Exp Cell Res"},{"issue":"1","key":"3530_CR47","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2174\/1568009023334033","volume":"2","author":"JS Damiano","year":"2002","unstructured":"Damiano JS. Integrins as novel drug targets for overcoming innate drug resistance. Curr Cancer Drug Targets. 2002;2(1):37\u201343.","journal-title":"Curr Cancer Drug Targets"},{"issue":"2","key":"3530_CR48","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s10549-022-06569-5","volume":"193","author":"R Assidicky","year":"2022","unstructured":"Assidicky R, et al. Targeting HIF1-alpha\/miR-326\/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer. Breast Cancer Res Treat. 2022;193(2):331\u201348.","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"3530_CR49","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41419-024-06843-y","volume":"15","author":"H Lu","year":"2024","unstructured":"Lu H, et al. IGFBP2\/ITGA5 promotes gefitinib resistance via activating STAT3\/CXCL1 axis in non-small cell lung cancer. Cell Death Dis. 2024;15(6):447.","journal-title":"Cell Death Dis"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03530-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03530-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03530-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T14:08:33Z","timestamp":1759759713000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03530-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3530"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03530-y","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"18 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This manuscript is a systematic review article and does not require approval by an ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Non-financial competing interest statement: Ahmed Al-Samadi is an Editorial Board Member of Discover Oncology, but he was not involved in the handling or decision-making process related to this submission.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1817"}}